Couzigou et al reported risk factors for urolithiasis in HIV-positive patients treated with the protease inhibitor atazanavir. These can help identify a patient at increase risk for urinary tract lithiasis and may suggest ways to reduce the risk. The authors are from multiple hospitals in France.
